HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via Google Scholar Google Scholar Articles by Cavalieri, R. R. Articles by Sairenji, E. Search for Related Content PubMed PubMed Citation Articles by Cavalieri, R. R. Articles by Sairenji, E.

Selenite (⁷⁵Se) as Tumor-Localizing Agent in Man^1,2,

San Francisco, California

ABSTRACT

To a degree which permits visualization of the tumor by scintillation scanning, ⁷⁵Se labeled selenite (SeO₃⁼) has been shown to localize in intracranial, intrathoracic, and intraabdominal neoplasms of humans. Assays of specimens of tumors obtained at operation or autopsy yielded concentrations of ⁷⁵Se ranging from 0.8 to 4.6 times the level in plasma. The results of distribution studies showed relatively high concentrations of label in liver and kidney and low levels in skeletal muscle. The calculated total-body radiation exposure based on a diagnostic dose of 4.0 µC per kg body weight and an average effective T of 43 days (for 75% of the administered dose) is 1.14 rads. Preliminary clinical experience indicates that ⁷⁵Se selenite may offer specific tumor-localizing properties not found in other currently used agents.

FOOTNOTES

¹ From the Radioisotope Service, Veterans Administration Hospital, San Francisco, and the Radioactivity Research Center, University of California, San Francisco Medical Center, San Francisco, California.

² Presented in part at the Twelfth Annual Meeting of the Society of Nuclear Medicine, June 17–19, 1965.